A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE DOSES OF ISIS 416858 (IONIS-FXIRX AN ANTISENSE INHIBITOR OF FACTOR XI), ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS.

Registry ID

ISIS 416858-CS5

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

IONIS PHARMACEUTICALS INC

Start date

2018-07-03

Last update

2017-10-16

Conditions

• RENAL FAILURE

Related clinical trials

• A PHASE 1 AND PHARMACOKINETIC STUDY OF DABRAFENIB (GSK2118436B) IN PATIENTS WITH BRAFV600X MUTATIONS AND RENAL OR HEPATIC DYSFUNCTION.

View on source registry